TNI BioTech's announcement that it will partner with leading Chinese pharmaceutical company Hubei Qianjiang Pharmaceutical in developing anti-cancer drugs for marketing in China is the latest confirmation of the company's intended long-term international orientation. Citizens of industrialized countries like the U.S. generally have more access to intensive and costly high-tech medicines and treatment options than in other parts of the world. It's a situation that represents new potential markets for developers of alternative drugs. In addition, such markets can also represent financial and other resources for faster development, approval, production, and marketing of new drugs.
In the case of the China deal, Hubei Qianjiang Pharmaceutical will provide $1.6 million for pre-clinical work in developing TNI's IRT-101 and IRT-102 immunotherapy drugs, in addition to offering a solid link to the intricacies of the Chinese drug market. After completion of the pre-clinical studies, Hubei will provide the funding for clinical trials in China to have Methionine Enkephalin approved as a new drug for the treatment of cancer.
Earlier, TNI announced an agreement to open an outpatient clinic in Malawi, Africa, for the treatment of cancer and infectious diseases, in conjunction with GB Oncology & Imaging Group. Infection-related cancers are especially problematic in people infected with HIV, which is a major factor in Malawi. Cancer patient survival rates in the country are very low due to a lack of early diagnosis and treatment.
TNI also recently announced the building of a new pharmaceutical plant in South America. The plant, located in Managua, Nicaragua, will produce the company's IRT-103 active immunotherapy drug for use against HIV/AIDS and tumor cells. In a unique arrangement, two of the owners of Pharmaceutical Care Consultants of South Florida, the leading outlet for the supply of IRT-103 (LDN) for over ten years, have agreed to head up the QC and QA aspects of the new plant.
For more information, visit tnibiotech.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net